http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2043059-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-86 |
| filingDate | 1980-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1980-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-2043059-A |
| titleOfInvention | Furochromones |
| abstract | A furochromone of the formula <IMAGE> wherein A is -CH=CR13-, -CX=CR14, -C[CH2S(O)nR10]=-C(CH3)-, -CH2-CHR14- or -CHR17-, in which n is zero, one or 2; R10 is C1-5 alkyl; R13 is isopropyl, C4-8 alkyl, (C1-7 alkoxy)methyl, (C1-7 alkylthio)methyl, trifluoromethyl, optionally substituted phenoxymethyl or phenylthiomethyl in which any substituents are selected from chlorine, fluorine, trifluoromethyl, C1-3 alkyl and C1-3 alkoxy, C3-10 cycloalkyl, (C1-5 alkylthio)methyl, (C1-5 alkylsulfinyl)methyl, (C1-5 alkylsulfonyl)methyl or -CH2NR8R9 in which either R8 and R9 are the same or different and are each hydrogen, C1-12 alkyl or C6-12 aryl or NR8R9 is an optionally substituted saturated or unsaturated C2-7 heterocyclic ring with up to 2 additional heteroatoms selected from oxygen, nitrogen and sulfur, and from 4 to 8 atoms in the ring, any substituents being selected from C1-4 alkyl, (C1-7 alkoxy)methyl, (C1-7 alkylthio)methyl, C1-4 hydroxyalkyl and phenyl; R14 is hydrogen, C1-8 alkyl, (C1-7 alkoxy)methyl, (C1-7 alkylthio)methyl, trifluoromethyl, optionally substituted phenoxymethyl or phenylthiomethyl as defined above or C3-10 cycloalkyl; R17 is hydrogen or C1-8 alkyl; and X is chlorine, bromine or iodine; one of R3 and R4 is methoxy and the other is hydrogen or methoxy, provided that R13 is not -CH2NR8R9 when R4 is hydrogen; and one of R20 and R21 is hydrogen and the other is hydroxy when A is -CH2-CHR14- or R20 and R21 together are oxo when A is not -CH2-CHR14-; or a pharmacologically acceptable salt thereof when R13 is -CH2NR8R9. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9002129-A1 |
| priorityDate | 1979-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 152.